BioMarin Announces Third Quarter 2009 Financi...(------ ------ Total asse...),Health

Date:10/28/2009

------ ------ Total assets $906,695 $869,357 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $59,033 $63,921 Acquisition obligation, net of discount 70,741 - Deferred revenue 307 149 --- --- Total current liabilities 130,081 64,070 Convertible debt 497,083 497,083 Other long-term liabilities 2,856 4,351 ----- ----- Total liabilities 630,020 565,504 ------- ------- Stockholders' equity: Common stock, $0.001 par value: 250,000,000 shares authorized at December 31, 2008 and September 30, 2009; 99,868,145 and 100,723,649 shares issued and outstanding at December 31, 2008 and September 30, 2009, respectively 100 101 Additional paid-in capital 852,947 887,966 Company common stock held by deferred compensation plan (882) (1,715) Accumulated other comprehensive income 1,106 (704) Accumulated deficit (576,596) (581,795) -------- -------- Total stockholders' equity 276,675 303,853
'/>"/>

SOURCE BioMarin Pharmaceutical Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call